About Cell division cycle protein 20 homolog
Cell division cycle protein 20 homolog (CDC20) is a protein
from Homo sapiens identified by UniProt accession
Q12834, 499 residues long.
MolForge cross-references it against 0 known binders and
279 disease associations.
Target properties
| Protein name | Cell division cycle protein 20 homolog |
| UniProt accession | Q12834 |
| Gene | CDC20 |
| Organism | Homo sapiens |
| Length | 499 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (279)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- ovarian cancer · score 0.25
- breast adenocarcinoma · score 0.25
- lung adenocarcinoma · score 0.20
- endometrial cancer · score 0.18
- clear cell renal carcinoma · score 0.18
- esophageal cancer · score 0.16
- hepatocellular carcinoma · score 0.13
- systolic blood pressure · score 0.12
- neoplasm · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12834-F1 | alphafold | PREDICTED | 84.12 | — |
Amino-acid sequence (499 residues)
MAQFAFESDL HSLLQLDAPI PNAPPARWQR KAKEAAGPAP SPMRAANRSH SAGRTPGRTP GKSSSKVQTT PSKPGGDRYI PHRSAAQMEV ASFLLSKENQ PENSQTPTKK EHQKAWALNL NGFDVEEAKI LRLSGKPQNA PEGYQNRLKV LYSQKATPGS SRKTCRYIPS LPDRILDAPE IRNDYYLNLV DWSSGNVLAV ALDNSVYLWS ASSGDILQLL QMEQPGEYIS SVAWIKEGNY LAVGTSSAEV QLWDVQQQKR LRNMTSHSAR VGSLSWNSYI LSSGSRSGHI HHHDVRVAEH HVATLSGHSQ EVCGLRWAPD GRHLASGGND NLVNVWPSAP GEGGWVPLQT FTQHQGAVKA VAWCPWQSNV LATGGGTSDR HIRIWNVCSG ACLSAVDAHS QVCSILWSPH YKELISGHGF AQNQLVIWKY PTMAKVAELK GHTSRVLSLT MSPDGATVAS AAADETLRLW RCFELDPARR REREKASAAK SSLIHQGIR
Explore Cell division cycle protein 20 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets